Tuesday, April 06, 2021 2:37:26 PM
https://www.marketwatch.com/press-release/oral-mucositis-drugs-market-size-2021-2026-industry-trends-size-segments-competitors-classification-growth-up-and-down-stream-industry-analysis-and-forecast-2021-02-15
https://drug-dev.com/gastrointestinal-drugs-market-to-hit-48-4-billion/
https://www.businesswire.com/news/home/20210210005504/en/Global-Anti-Viral-Drug-Therapy-Market-2020-to-2030---Opportunities-and-Strategies-with-COVID-19-Implications-and-Growth---ResearchAndMarkets.com
https://www.gminsights.com/pressrelease/oncology-market#:~:text=Oncology%20Market%20size%20is%20set,by%20Global%20Market%20Insights%2C%20Inc.
The world's best-selling drug, Humira, took 15 years for its sales to go from $250M in 2003 to nearly $20B in 2018. The point here is that approved-effective drugs take time to ramp-up to the billion-dollar+ sales arena.
Additonally, oral mucositis is not even, globally, a billion-dollar market and the gastrointestinal market comes with major competition from the likes of AbbVie, JNJ, Allergan & AstraZeneca. Also:
https://drug-dev.com/gastrointestinal-drugs-market-to-hit-48-4-billion/
B-COVID advantage over other B/indications is: Market Opportunity
https://www.google.com/search?q=market+opportunity+definition&rlz=1CAKDUD_enUS930&oq=market+opportunity&aqs=chrome.2.69i57j0l9.10398j0j7&sourceid=chrome&ie=UTF-8
Globally, substantial market opportunities await B-COVID in the form of bulk billion-dollar buyers around the world and the coronavirus variants will only serve to make B-COVID even more valuable.
Leo is working hard to get B-COVID up and running and, IMO, he would be unwise to expend IPIX's precious capital on further development of B-OM and B-UC/CD (gastrointestinal area). IMO, Leo should be solely focused on B-COVID and the development of B as a broad spectrum anti-viral drug therapy (AVDT).
B-COVID, judging from the sales experience of vaccines, will generate billion$ in MONTHS not YEARS and once revenues start rolling in Leo, IMO,should turn his attention back to the development of "K" for Ovarian cancer because Ovarian Carcinomas are
http://www.ipharminc.com/therapeutic-areas/
I believe the course of action I am proposing is consistent with the sales projections and market size for the above indications.
The logic here is very simple and best stated by the late bank robber Willie Sutton who, arrested and walking into FBI HQ, was asked, "Why do you rob banks?" Sutton's response:
“Because that's where the money is.”
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM